The 10-second takeaway
For the quarter ended March 31 (Q1), WellPoint missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue improved and GAAP earnings per share grew.
Margins dropped across the board.
WellPoint logged revenue of $15.15 billion. The 14 analysts polled by S&P Capital IQ expected revenue of $15.40 billion on the same basis. GAAP reported sales were 3.5% higher than the prior-year quarter's $14.89 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $2.34. The 20 earnings estimates compiled by S&P Capital IQ predicted $2.26 per share on the same basis. GAAP EPS of $2.53 for Q1 were 3.7% higher than the prior-year quarter's $2.44 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 23.6%, 100 basis points worse than the prior-year quarter. Operating margin was 9.2%, 110 basis points worse than the prior-year quarter. Net margin was 5.6%, 60 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $15.52 billion. On the bottom line, the average EPS estimate is $2.08.
Next year's average estimate for revenue is $62.31 billion. The average EPS estimate is $7.73.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 911 members out of 969 rating the stock outperform, and 58 members rating it underperform. Among 301 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 294 give WellPoint a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WellPoint is outperform, with an average price target of $84.88.
The healthcare investing landscape is littered with also-rans and a few major winners. Is WellPoint prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add WellPoint to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of WellPoint. Motley Fool newsletter services have recommended buying shares of WellPoint. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.